# Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery

> **NCT07734766** · PHASE4 · NOT_YET_RECRUITING · sponsor: **Second Affiliated Hospital of Xi'an Jiaotong University** · enrollment: 45 (estimated)

## Conditions studied

- Hepato Cellular Carcinoma

## Interventions

- **DRUG:** Ebastine

## Key facts

- **NCT ID:** NCT07734766
- **Lead sponsor:** Second Affiliated Hospital of Xi'an Jiaotong University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-10-01
- **Primary completion:** 2029-03-01
- **Final completion:** 2030-03-01
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2026-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07734766

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07734766, "Ebastine for Adjuvant Treatment of Tumor Budding-Positive Liver Cancer After Surgery". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07734766. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*